Penumbra Inc (PEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Penumbra Inc (PEN) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($86.97 Million) by net assets ($1.47 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Penumbra Inc (PEN) defensive interval to measure how many days the company can operate on defensive assets alone.
Penumbra Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Penumbra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Penumbra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Penumbra Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GAIL (India) Limited
NSE:GAIL
|
0.065x |
|
Far EasTone Telecommunications Co Ltd
TW:4904
|
0.095x |
|
ZTO Express (Cayman) Inc
NYSE:ZTO
|
0.178x |
|
Pro Medicus Ltd
AU:PME
|
0.178x |
|
TransUnion
NYSE:TRU
|
0.017x |
|
United States Steel Corporation
NYSE:X
|
-0.023x |
|
WILMAR INTL ADR/10 SD-50
F:RTH
|
N/A |
|
Ivanhoe Mines Ltd.
TO:IVN
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Penumbra Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Penumbra Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Penumbra Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.43 Billion | $238.66 Million | 0.167x | +14.20% |
| 2024-12-31 | $1.15 Billion | $168.48 Million | 0.146x | +77.31% |
| 2023-12-31 | $1.18 Billion | $97.33 Million | 0.083x | +248.16% |
| 2022-12-31 | $998.86 Million | $-55.66 Million | -0.056x | -659.43% |
| 2021-12-31 | $953.93 Million | $9.50 Million | 0.010x | +119.11% |
| 2020-12-31 | $637.79 Million | $-33.24 Million | -0.052x | -194.97% |
| 2019-12-31 | $485.61 Million | $26.65 Million | 0.055x | -19.52% |
| 2018-12-31 | $422.42 Million | $28.81 Million | 0.068x | +115.17% |
| 2017-12-31 | $400.41 Million | $12.69 Million | 0.032x | +165.97% |
| 2016-12-31 | $266.55 Million | $-12.81 Million | -0.048x | +49.85% |
| 2015-12-31 | $232.52 Million | $-22.28 Million | -0.096x | -118.55% |
| 2014-12-31 | $-12.37 Million | $-6.39 Million | 0.516x | +22.61% |
| 2013-12-31 | $-8.06 Million | $-3.40 Million | 0.421x | -- |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombecto… Read more